INNOVIVA, INC. Unamortized Debt Issuance Expense
INNOVIVA, INC. (INVA) had Unamortized Debt Issuance Expense of $11.39 million as of 2017-03-31, per its 10-Q filed 2017-05-05.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2017-05-05
- 2017-03-31: Unamortized Debt Issuance Expense $11.39M.
- 2016-12-31: Unamortized Debt Issuance Expense $12.08M.
- 2016-09-30: Unamortized Debt Issuance Expense $12.85M.
- 2016-06-30: Unamortized Debt Issuance Expense $13.57M.
| Period end | Unamortized Debt Issuance Expense |
|---|---|
| 2017-03-31 | $11.39M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $12.08M 10-Q · filed 2017-05-05 |
| 2016-09-30 | $12.85M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $13.57M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $14.44M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $15.14M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |